PRODUCTS
BY COMPANY NAME
BY THERAPEUTIC DESCRIPTION
SOLUPHARM
PATAXEL® 30mg/5mL
CONCENTRATE FOR SOLUTION FOR INFUSION
Ovarian cancer: As first line chemotherapy of ovarian cancer, Pataxel is indicated in patients with advanced or residual disease (> 1cm) after initial laparotamy, in combination with cisplatin. As second-line chemotherapy of ovarian cancer, Pataxel is indicated in the treatment of metastatic ovarian cancer after failure of standard platinum based therapy. Breast cancer: As an adjuvant treatment, Pataxel is indicated for the treatment of patients with node-positive breast cancer following anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with Pataxel should be considered as an alternative to prolonged AC therapy. Pataxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is appropriate or in combination with trastuzumab, in patients with HER-2 over-expression at a 3+ level, as determined by immunohistochemistry and for whom anthrac
For more info about this product. Download